首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   22471篇
  免费   1550篇
  国内免费   722篇
耳鼻咽喉   258篇
儿科学   120篇
妇产科学   409篇
基础医学   983篇
口腔科学   189篇
临床医学   1963篇
内科学   3093篇
皮肤病学   110篇
神经病学   535篇
特种医学   444篇
外国民族医学   12篇
外科学   7004篇
综合类   3670篇
预防医学   703篇
眼科学   178篇
药学   1847篇
  37篇
中国医学   683篇
肿瘤学   2505篇
  2024年   6篇
  2023年   446篇
  2022年   582篇
  2021年   892篇
  2020年   958篇
  2019年   688篇
  2018年   648篇
  2017年   792篇
  2016年   877篇
  2015年   821篇
  2014年   1710篇
  2013年   1591篇
  2012年   1422篇
  2011年   1538篇
  2010年   1189篇
  2009年   1139篇
  2008年   1157篇
  2007年   1082篇
  2006年   973篇
  2005年   888篇
  2004年   781篇
  2003年   636篇
  2002年   524篇
  2001年   434篇
  2000年   386篇
  1999年   352篇
  1998年   316篇
  1997年   261篇
  1996年   251篇
  1995年   250篇
  1994年   212篇
  1993年   162篇
  1992年   117篇
  1991年   116篇
  1990年   75篇
  1989年   76篇
  1988年   53篇
  1987年   52篇
  1986年   51篇
  1985年   39篇
  1984年   43篇
  1983年   21篇
  1982年   33篇
  1981年   20篇
  1980年   17篇
  1979年   14篇
  1978年   18篇
  1977年   12篇
  1976年   7篇
  1975年   5篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
膀胱癌是泌尿系统常见的肿瘤,其中90%以上的膀胱癌病理类型为尿路上皮癌,按照肿瘤浸润深度可分为非肌层浸润性尿路上皮癌(Non muscle invasive bladder cancer,NMIBC)和肌层浸润性尿路上皮癌。NMIBC主要是指肿瘤侵及固有层(T1)、粘膜层(Ta)和原位癌(Tis),其预后较好。其中Ta、T1期肿瘤占大多数,两者虽然都属于NMIBC,但生物学特性不同,由于固有层血管和淋巴管丰富,故T1期肿瘤较容易发生扩散和复发。本文将重点针对T1期高级别尿路上皮癌的各种治疗方式,包括手术治疗、介入治疗、药物化疗和免疫治疗等方面做一综述,特别探讨了如何利用手术治疗方式以及手术治疗联合化疗提高治疗效果,减少复发,提高生存时间。  相似文献   
2.
BackgroundSurgical resection is recommended for patients with resectable acinar cell carcinoma (ACC). The aim of this study was to investigate the clinical characteristics and surgical outcomes of resectable ACC in comparison to pancreatic ductal adenocarcinoma (PDAC).MethodA retrospective analysis was performed on all patients who consecutively underwent radical resection with pathologically confirmed ACC and PDAC from December 2011 to December 2018. Clinicopathologic characteristics and follow-up information were analyzed. A 1:3 propensity score matching (PSM) method was used to minimize the bias between ACC and PDAC.ResultsA total of 26 patients with ACC and 1351 with PDAC were included. Compared to PDAC, ACC tended to be larger (4.5 vs. 3.0 cm; p < 0.001) and more frequently located in the pancreatic body/tail (61.5% vs. 36.6%, p = 0.009), with lower total bilirubin levels, lower neutrophil lymphocyte ratio (NLR) levels and lower carbohydrate antigen 19-9 (CA19-9) levels and carcinoembryonic antigen (CEA) levels. There was no difference in postoperative morbidities in patients with ACC and PDAC. The median OS and RFS were longer in ACC when compared to PDAC (OS: 43.5 mo vs. 19.0 mo, p = 0.004; RFS: 24.5 mo vs. 11.6 mo, p = 0.023). After the 1:3 PSM, ACC remained to be a better histological type for OS (p = 0.024), but had comparable RFS with PDAC (p = 0.164).ConclusionPatients with ACC after radical resection had better OS than that with PDAC. However, ACC is also an aggressive tumor with a similar trend of RFS with PDAC after the matching, necessitating the multidisciplinary treatment for resectable ACC disease.  相似文献   
3.
目的:通过对接受腹腔镜直肠癌根治(total mesorectal excision,TME)手术患者的术后随访,探究保留左半结肠血管对术后便秘及相关并发症的影响。方法:我院普外科2015年05月至2017年05月共收治的93例直肠肠癌根治手术患者进行回顾性分析。结果:对于病人的年龄、性别、BMI、术前CEA、术中出血量、吻合口瘘、术后肿瘤复发率,是否保留左半结肠血管方面无差异(P>0.05)。低位结扎组在术后肠道功能恢复、吻合口炎症以及术后便秘发生率中明显优于高位结扎组(P<0.05);高位结扎组在手术时间上优于低位结扎组(P<0.05)。结论:保留左半结肠的TME手术可以完成同样的淋巴结清扫,虽然术中用时较长但一定程度上保护了肠道的血运及神经,降低了术后便秘的发生率,值得临床进一步研究与推广。  相似文献   
4.
5.
6.
7.
ObjectiveNerve-sparing radical hysterectomy (NSRH) decreases the negative postoperative consequences of radical surgery for cervical cancer, such as bladder evacuation disorders, colorectal motility disorders, and sexual dysfunction. The aim of this study was to prospectively assess the sexuality and quality of life in a group of women who underwent NSRH with lymphadenectomy for cervical cancer.Materials and methodsA total of 65 patients with early-stage cervical cancer underwent NSRH between 2014 and 2016. Patient examinations and questionnaire surveys (Female Sexual Function Index questionnaire and European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-CX24) were conducted, before and one year after the surgery.ResultsAfter the exclusion of 19 sexually inactive women and 10 women who received adjuvant anticancer treatment, 36 sexually active patients treated solely with nerve-sparing surgery were eligible for evaluation. The mean age was 47 years. The average preoperative vaginal length was 9.4 cm, whereas the postoperative length was shortened to 7.1 cm. This study showed no negative impact of NSRH on sexual desire, arousal, satisfaction, orgasm, pain, sexual activity, sexual enjoyment, and sexual worry. The worsening of sexual functioning was recorded during the one-year follow-up. The QLQ-C30 questionnaire confirmed postoperative improvement in global health status and role, emotional, and social functioning.ConclusionOur study showed using standardized questionnaires that NSRH has no negative impact on sexual desire, arousal, satisfaction, orgasm, pain, sexual activity, frequency of sexual intercourse, sexual enjoyment, and sexual worry, while only the worsening of sexual functioning was recorded. Moreover, NSRH did not cause postoperative deterioration in the quality of life parameters.  相似文献   
8.
目的探讨预防性护理干预在女性垂体瘤切除术患者围手术期的应用效果。方法选取2019年11月至2020年12月中国科学技术大学附属第一医院南区收治的84例女性垂体瘤切除术患者作为研究对象,根据护理方法的不同分为观察组(42例)和对照组(42例),分别实施预防性护理干预和常规护理,比较两组患者术后并发症发生率、护理满意度及护理前后焦虑自评量表(SAS)和抑郁自评量表(SDS)评分。结果观察组患者术后并发症总发生率低于对照组,差异有统计学意义(P<0.05)。两组护理后的SAS和SDS评分低于护理前,观察组护理后SAS和SDS评分低于对照组,差异有统计学意义(P<0.05)。观察组患者的护理总满意度高于对照组,差异有统计学意义(P<0.05)。结论女性垂体瘤切除术患者实施预防性护理干预,可提高术后并发症的防治效果,促进患者快速、良好康复。  相似文献   
9.
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone.  相似文献   
10.
目的研究结直肠息肉内镜切除术后迟发性出血的危险因素。方法统计3203例结直肠息肉切除术患者术后发生迟发性出血情况,分析性别、年龄、息肉位置、息肉病理类型、术中出血、冠心病、高血压、糖尿病对结直肠息肉内镜切除术后发生迟发性出血的影响。结果结直肠息肉内镜切除术后有78例发生迟发性出血,占比2.44%,其中内镜治疗术后24 h~4 d内发生的有55例患者,最迟的发生在术后14 d。发生迟发性出血的患者中男48例,女30例;年龄<60岁46例,≥60岁32例;息肉位置为直肠24例,左半结肠22例,右半结肠32例;增生性息肉9例,炎性息肉13例,腺瘤性息肉56例;术中出血23例;冠心病4例;高血压22例;糖尿病5例。未发生迟发性出血的患者中男2037例,女1088例;年龄<60岁1799例,≥60岁1326例;息肉位置为直肠627例,左半结肠1447例,右半结肠1051例;增生性息肉325例,炎性息肉596例,腺瘤性息肉2204例;术中出血164例;冠心病110例;高血压245例;糖尿病199例。发生迟发性出血的患者与未发生迟发性出血的患者息肉位置、术中是否出血、有无高血压情况比较,差异具有统计学意义(P<0.05)。结论息肉位置、术中是否出血、有无高血压是结直肠息肉内镜切除术后迟发性出血的影响因素,在临床治疗中,医生需要格外提高注意,对患者进行监督与照顾,杜绝迟发性出血情况的发生。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号